% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The terms of the non-tradable CVR include an additional payment of up to $2.00 if certain sales milestones are achieved. The CVR will entitle each Trius stockholder to receive $1.00 per share if net sales of tedizolid in the U.S., Canada and Europe are greater than or equal to $125 million in 2016 and up to an additional $1.00 per share, paid on a pro rata basis, for 2016 net sales between $125 million and $135 million.
    Barclays is acting as the exclusive financial advisor to Cubist, and Ropes & Gray LLP is serving as its legal counsel. Citi and Centerview Partners LLC are acting as financial advisors to Trius, and Cooley LLP is serving as its legal counsel.

  • Reply to


    by skylesa Dec 8, 2014 9:16 AM

    are they burying the CVR's in a paper shuffle? Had difficulty trying to get any info on them.

Must Watch